144 related articles for article (PubMed ID: 30409254)
1. SPECT Molecular Imaging in Familial Parkinson's Disease.
Varrone A; Pellecchia MT
Int Rev Neurobiol; 2018; 142():225-260. PubMed ID: 30409254
[TBL] [Abstract][Full Text] [Related]
2. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
[TBL] [Abstract][Full Text] [Related]
3. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease.
Booij J; Knol RJ
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S425-8. PubMed ID: 18267276
[TBL] [Abstract][Full Text] [Related]
4. Molecular Imaging of the Dopamine Transporter.
Palermo G; Ceravolo R
Cells; 2019 Aug; 8(8):. PubMed ID: 31405186
[TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice.
Ba F; Martin WR
Parkinsonism Relat Disord; 2015 Feb; 21(2):87-94. PubMed ID: 25487733
[TBL] [Abstract][Full Text] [Related]
6. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
de Natale ER; Niccolini F; Wilson H; Politis M
Int Rev Neurobiol; 2018; 141():131-172. PubMed ID: 30314595
[TBL] [Abstract][Full Text] [Related]
7. Role of DAT-SPECT in the diagnostic work up of parkinsonism.
Scherfler C; Schwarz J; Antonini A; Grosset D; Valldeoriola F; Marek K; Oertel W; Tolosa E; Lees AJ; Poewe W
Mov Disord; 2007 Jul; 22(9):1229-38. PubMed ID: 17486648
[TBL] [Abstract][Full Text] [Related]
8. Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.
Hutchison RM; Evans KC; Fox T; Yang M; Barakos J; Bedell BJ; Cedarbaum JM; Brys M; Siderowf A; Lang AE
BMC Neurol; 2021 Nov; 21(1):459. PubMed ID: 34814867
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging of dopamine transporters.
Brooks DJ
Ageing Res Rev; 2016 Sep; 30():114-21. PubMed ID: 26802555
[TBL] [Abstract][Full Text] [Related]
10. The role of SPECT imaging of the dopaminergic system in translational research on Parkinson's disease.
Suwijn SR; de Bruin K; de Bie RM; Booij J
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S184-6. PubMed ID: 24262177
[TBL] [Abstract][Full Text] [Related]
11. SPECT molecular imaging in Parkinson's disease.
Wang L; Zhang Q; Li H; Zhang H
J Biomed Biotechnol; 2012; 2012():412486. PubMed ID: 22529704
[TBL] [Abstract][Full Text] [Related]
12. DAT-SPECT imaging in cases of drug-induced parkinsonism in a specialty movement disorders practice.
Yomtoob J; Koloms K; Bega D
Parkinsonism Relat Disord; 2018 Aug; 53():37-41. PubMed ID: 29748111
[TBL] [Abstract][Full Text] [Related]
13. PET Molecular Imaging in Familial Parkinson's Disease.
Matarazzo M; Wile D; Mackenzie M; Stoessl AJ
Int Rev Neurobiol; 2018; 142():177-223. PubMed ID: 30409253
[TBL] [Abstract][Full Text] [Related]
14. Dopamine transporter (DAT) imaging in Parkinson's disease and related disorders.
Brücke T; Brücke C
J Neural Transm (Vienna); 2022 Jun; 129(5-6):581-594. PubMed ID: 34910248
[TBL] [Abstract][Full Text] [Related]
15. Dopamine transporter single photon emission computed tomography (DaT-SPECT) use in the diagnosis and clinical management of parkinsonism: an 8-year retrospective study.
Tsang K; Walker R
J Neurol; 2023 May; 270(5):2550-2558. PubMed ID: 36795149
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.
Suwijn SR; van Boheemen CJ; de Haan RJ; Tissingh G; Booij J; de Bie RM
EJNMMI Res; 2015; 5():12. PubMed ID: 25853018
[TBL] [Abstract][Full Text] [Related]
17. DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.
Artzi M; Even-Sapir E; Lerman Shacham H; Thaler A; Urterger AO; Bressman S; Marder K; Hendler T; Giladi N; Ben Bashat D; Mirelman A
PLoS One; 2017; 12(4):e0175424. PubMed ID: 28406934
[TBL] [Abstract][Full Text] [Related]
18. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism.
Kim JM; Hong S; Kim GP; Choi YJ; Kim YK; Park SS; Kim SE; Jeon BS
Arch Neurol; 2007 Oct; 64(10):1510-8. PubMed ID: 17923635
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome.
Kessler KR; Hamscho N; Morales B; Menzel C; Barrero F; Vives F; Gispert S; Auburger G
J Neural Transm (Vienna); 2005 Oct; 112(10):1345-53. PubMed ID: 15785866
[TBL] [Abstract][Full Text] [Related]
20. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease.
Alvarez-Fischer D; Blessmann G; Trosowski C; Béhé M; Schurrat T; Hartmann A; Behr TM; Oertel WH; Höglinger GU; Höffken H
Neuroimage; 2007 Oct; 38(1):5-12. PubMed ID: 17716921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
